ID   TT2609-A02
AC   CVCL_A594
DR   DSMZ; ACC-859
DR   DSMZCellDive; ACC-859
DR   Wikidata; Q54973222
RX   PubMed=11716037;
CC   Population: Caucasian.
CC   Doubling time: 68 hours (PubMed=11716037); ~100 hours (DSMZ=ACC-859).
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): DSMZ=ACC-859
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 9,11
ST   D18S51: 14
ST   D19S433: 13,15
ST   D21S11: 28,30
ST   D2S1338: 19,25
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 8,10
ST   D8S1179: 12,13
ST   FGA: 22,25
ST   Penta D: 12,14
ST   Penta E: 5
ST   TH01: 8,9.3
ST   TPOX: 8,12
ST   vWA: 17,18
DI   NCIt; C8054; Thyroid gland follicular carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A595 ! TT2609-B02
OI   CVCL_2218 ! TT2609-C02
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 02-05-24; Version: 16
//
RX   PubMed=11716037; DOI=10.1089/105072501753210966;
RA   Geldof A.A., Versteegh R.T., van Mourik J.C., Rooimans M.A.,
RA   Arwert F., Hermsen M.A.J.A., Schadee-Eestermans I.L.,
RA   van Dongen G.A.M.S., van der Valk P., van der Poest Clement E.H.,
RA   Lips P., Teule G.J.J.;
RT   "Clonally related but phenotypically divergent human cancer cell lines
RT   derived from a single follicular thyroid cancer recurrence (TT2609).";
RL   Thyroid 11:909-917(2001).
//